US5061476A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radiolabeled colloid compositions and method for preparing same
Assignee: Mallinckrodt Inc
•
Filing: 1989-12-27
•
Granted: 1991-10-29
•
Expires: 2009-12-27
Abstract
Abstract Radiolabeled colloid compositions and a method for the preparation of radionuclide-colloid compositions useful in the treatment of rheumatoid arthritis are disclosed. A radionuclide selected from the group consisting of Sm-135, Ho-166, In-155m, Y-90, Gd-159 La-140, Lu-177, or Yb-175 is sorbed to a previously prepared iron-hydroxide colloid. The radiolabeled colloid compositions are comprised of spherical aggregations containing greater than 50% of the radioactive metal in iron-hydroxide particles. The method produces stable radionuclide iron-hydroxide compositions which are useful in therapeutic procedures such as radiation synovectomy.
Inventors
- 👤 Jaime Simon
- 👤 Lance A. Cooper
- 👤 Kenneth McMillan
- 👤 David A. Wilson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 10:29
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1217; A61P; A61P19/00; A61P19/02; A61P29/00; A61K2121/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
50 words
A method for producing a radioactive composition, comprising the steps of: (a) preparing an iron-hydroxide colloid by precipitating an iron solution with an alkali metal hydroxide; and (b) sorbing onto the iron-hydroxide colloid a radionuclide selected from the group consisting of Sm-153, Ho-166, In-115m, Y-90, Gd-159, La-140, Lu-177 and Yb-175.
Claim 2
Independent Claim
50 words
A method for producing a radioactive composition, comprising the steps of: (a) preparing an iron-hydroxide colloid by precipitating an iron solution with an alkali metal hydroxide; and (b) sorbing onto the iron-hydroxide colloid a radionuclide selected from the group consisting of Sm-153, Ho-166, In-115m, Y-90, Gd-159, La-140, Lu-177 and Yb-175.
Claim 3
Dependent Claim
18 words
The method of claim 1, wherein the iron solution of step (a) is a solution comprising iron (II).
Claim 4
Dependent Claim
18 words
The method of claim 1, wherein the iron solution of step (a) is a solution comprising iron (III).
Claim 5
Dependent Claim
22 words
The method of claim 1, wherein the radionuclide of step (b) is selected from the group consisting of Sm-153, Ho-166 and In-115m.
Claim 6
Dependent Claim
37 words
The method of claim 1, wherein said sorbing is accomplished by preparing a mixture of a radionuclide with the iron-hydroxide colloid wherein the mixture is further permitted to stand for a period of up to 30 minutes.
Claim 7
Dependent Claim
22 words
The method of claim 1, including the additional step of filtering the iron-hydroxide colloid formed in step (a) prior to step (b).
Claim 8
Dependent Claim
58 words
A composition comprising iron-hydroxide and a radionuclide selected from the group consisting of Sm-153, Ho-166, In-115m, Y-90, Gd-159, La-140, Lu-177 and Yb-175, wherein greater than 50% of the radionuclide is contained within spherical aggregations of the iron hydroxide, and wherein particles of the composition are of a size sufficient to prevent significant leakage from a site of injection.
Claim 9
Dependent Claim
58 words
A composition comprising iron-hydroxide and a radionuclide selected from the group consisting of Sm-153, Ho-166, In-115m, Y-90, Gd-159, La-140, Lu-177 and Yb-175, wherein greater than 50% of the radionuclide is contained within spherical aggregations of the iron hydroxide, and wherein particles of the composition are of a size sufficient to prevent significant leakage from a site of injection.
Claim 10
Dependent Claim
16 words
The composition of claim 7, wherein said spherical aggregations contain greater than 70% of the radionuclide.
Claim 11
Dependent Claim
11 words
The composition of claim 7, wherein the iron-hydroxide is iron (II)-hydroxide.
Claim 12
Dependent Claim
11 words
The composition of claim 7, wherein the iron-hydroxide is iron (III)-hydroxide.
Claim 13
Dependent Claim
19 words
The composition of claim 7, wherein the radionuclide is selected from the group consisting of Sm-153, Ho-166, and In-115m.
Claim 14
Independent Claim
54 words
A method for the treatment of arthritis comprising sorbing a radionuclide selected from the group consisting of Sm-153, Ho-166, In-115m, Y-90, Gd-159, La-140, Ju-177 and Yb-175 onto a previously prepared iron-hydroxide colloid; and injecting into the synovium of a subject in need of such treatment a therapeutically effective amount of the composition thus formed.
Claim 15
Independent Claim
54 words
A method for the treatment of arthritis comprising sorbing a radionuclide selected from the group consisting of Sm-153, Ho-166, In-115m, Y-90, Gd-159, La-140, Ju-177 and Yb-175 onto a previously prepared iron-hydroxide colloid; and injecting into the synovium of a subject in need of such treatment a therapeutically effective amount of the composition thus formed.
Claim 16
Independent Claim
53 words
A method for the treatment of arthritis comprising injecting into the synovium of a subject in need of such treatment a therapeutically effective amount of a composition comprising iron-hydroxide and a radionuclide selected from the group consisting of Sm-153, Ho-166, In-115m, Y-90, Gd-159, the radionuclide is contained within spherical aggregations of the iron-hydroxide.
Claim 17
Independent Claim
53 words
A method for the treatment of arthritis comprising injecting into the synovium of a subject in need of such treatment a therapeutically effective amount of a composition comprising iron-hydroxide and a radionuclide selected from the group consisting of Sm-153, Ho-166, In-115m, Y-90, Gd-159, the radionuclide is contained within spherical aggregations of the iron-hydroxide.
Claim 18
Dependent Claim
16 words
The method of claim 13, wherein said spherical aggregations contain greater than 70% of the radionuclide.
Claim 19
Dependent Claim
13 words
The method of claim 13, wherein the iron hydroxide is iron (II) hydroxide.
Claim 20
Dependent Claim
13 words
The method of claim 13, wherein the iron hydroxide is iron (III) hydroxide.
Claim 21
Dependent Claim
19 words
The method of claim 13, wherein the radionuclide is selected from the group consisting of Sm-153, Ho-166 and In-115m.
Claim 22
Dependent Claim
11 words
The method of claim 13, wherein said arthritis is rheumatoid arthritis.
Claim 23
Dependent Claim
18 words
The method of claim 13, wherein said injecting is to the synovium of a joint of the subject.
Claim 24
Dependent Claim
11 words
The method of claim 13, wherein said subject is a mammal.
Claim 25
Dependent Claim
11 words
The method of claim 20, wherein said mammal is a human.
References Cited (Backward Citations)
US4898724A
Cited
US4897254A
Cited
US4752464A
Cited
US4849209A
Cited
US4758429A
Cited
US4906450A
Cited
US4915932A
Cited
US4889707A
Cited
US4970062A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-10-28 | 1995-04-29 | 1995-10-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-10-28 | 1999-04-29 | 1999-10-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-10-28 | 2003-04-29 | 2003-10-29 | $7700.00 | Window Closed / Lapsed |